Mass Tort Advertising Campaign
Oxbryta Marketing & Claimant Acquisition
Oxbryta (voxelotor) litigation follows one of the more striking pharmaceutical reversals in recent years: a sickle cell disease drug marketed as a breakthrough that Pfizer voluntarily withdrew from the market worldwide in September 2024, after data showed patients taking it experienced more of the painful vaso-occlusive crises it was supposed to reduce — and an imbalance in deaths. Plaintiffs allege Pfizer and Global Blood Therapeutics failed to warn patients and prescribers of those risks.
For plaintiff firms, a voluntary worldwide withdrawal is the cleanest liability signal a pharma tort can offer, and the affected population — sickle cell patients — is well-defined and reachable.
Oxbryta at a glance
- Substance / mechanism
- Voxelotor
- Manufacturer(s)
- Pfizer (Global Blood Therapeutics)
- Associated injuries
- Vaso-Occlusive Crises / Death
- Litigation status
- DEVELOPING
- Campaign intake
- Open
The litigation landscape
The withdrawal itself anchors the litigation narrative: Pfizer pulled Oxbryta from every market after clinical and registry data showed the drug's risks outweighed its benefits, roughly five years after the FDA's accelerated approval. Failure-to-warn and design-defect claims are building in filings across the country, and the litigation is developing rather than consolidated — the stage where early case inventory is accumulated at the lowest cost.
The claimant population is distinct: sickle cell disease disproportionately affects Black Americans, and the patient community is organized, active online, and acutely aware of the withdrawal. That makes both the injury story and the outreach path unusually clear for a pharma tort.
Who a campaign targets
Screening criteria firms typically apply in Oxbryta matters include:
- Documented Oxbryta (voxelotor) prescription and use
- Vaso-occlusive crises, hospitalization, stroke, or other serious events during or after use — or death of a family member who took the drug
- Medical records connecting the injury window to the period of use
- Claims within applicable limitations periods, generally running from the September 2024 withdrawal announcement
How MTAA runs Oxbryta campaigns
Oxbryta campaigns benefit from a rare combination: a specific, namable drug; a dramatic and documented withdrawal; and a patient community concentrated in identifiable geographies and online spaces. Creative that respects the sickle cell community and leads with the withdrawal facts screens efficiently and avoids the vagueness that inflates cost in broader pharma torts.
MTAA builds these campaigns with community-appropriate creative and screening aligned to intake counsel criteria — ask for the current pharma tort benchmarks on our market data page.
Pricing
Mass Tort Ad Agency runs Oxbryta campaigns on the same transparent model as every tort: actual Meta ad spend at cost plus a flat 15% management fee, a one-time $1,000 setup fee per tort, and $100 per signed retainer for CloudIntake qualification. No per-case markups, no lead resale, and the firm owns its ad account, pixel, creative, and claimant data.
Oxbryta advertising — common questions
Why was Oxbryta withdrawn?
Is there an Oxbryta MDL?
Who is the claimant population?
What makes this tort advertisable now?
Ready to run Oxbryta campaigns?
We build, run, and qualify Oxbryta claimant-acquisition campaigns end to end. Book a call and we'll walk you through the creative, audience, and intake plan.
Book a strategy call